Polycythemia Vera Treatment Market size is predicted to reach USD 45 billion by the end of 2036, growing at a CAGR of 7% during the forecast period i.e., 2024 – 2036. In the year 2023, the industry size of polycythemia vera treatment was USD 6 billion. The growth of this market can be ascribed to the development of new advanced treatments. Previously there was only one treatment for PV which was phlebotomy which consists of removing excess blood from the body. Recently, several new treatments have been developed such as Interferon alpha, JAK inhibitors, and myelosuppressive therapy. These treatments help patients manage lots of symptoms and enhance their quality of life.
In addition to this, increasing prevalence of polycythemia vera is anticipated to drive the polycythemia vera treatment market. Moreover, patients experience polycythemia vera symptoms over a long period of time. Before any visible symptoms appear, the disease is frequently discovered by chance during a routine exam that consists of a blood test. Early diagnosis increases the chance of rapid recovery in patients. As per data 1 in 3,300 people in the United States suffered from polycythemia vera.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~7% |
|
Base Year Market Size |
~USD 6 billion |
|
Forecast Year Market Size |
~USD 45 billion |
|
Regional Scope |
|
North America Market Forecast:
The North America polycythemia vera treatment market is expected to hold the highest growth rate of 34% from 2024 to 2036. The growth of this market can be attributed to various factors such as high demand for novel drug delivery system, the development of advanced medication, and increasing investment in research and development activities. Rogeinterferon alfa-2b-njft is being sought for the treatment of polycythemia vera (PV), and in May 2021, PharmaEssentia USA Corporation announced the resubmission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Europe Market Statistics
The polycythemia vera treatment market in the Europe is set to grow significantly during the estimated period. The increasing enhancement in diagnostic testing in the Europe region is poised to drive the growth of polycythemia vera treatment sector in the region.
Drug Class (Antimetabolite, Kinase Inhibitors, Alpha Interferon, Selective Serotonin Reuptake Inhibitors)
The antimetabolite segment is predicted to hold 35% share of the global polycythemia vera treatment market by the end of 2036. The growth can be predicted owing to its high success rate of treating people as compared to other drugs. It has proven itself as a popular therapeutic choice and is anticipated to grow steadily during the projected period.
Route of Administration (Oral, Intravenous, Intramascular, Subcutaneous)
The oral segment in the polycythemia vera treatment market is expected to grow significantly during the projection period. The technology for controlling a drug's rate of release and bioavailability has evolved dramatically, and oral administration is the most common method of medicine delivery. The same dosage of a drug is used, new oral delivery methods can increase its effectiveness. These and other developments also drive down the cost of manufacturing, which lowers the cost of treatment for patients.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North America Market Forecast:
The North America polycythemia vera treatment market is expected to hold the highest growth rate of 34% from 2024 to 2036. The growth of this market can be attributed to various factors such as high demand for novel drug delivery system, the development of advanced medication, and increasing investment in research and development activities. Rogeinterferon alfa-2b-njft is being sought for the treatment of polycythemia vera (PV), and in May 2021, PharmaEssentia USA Corporation announced the resubmission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Europe Market Statistics
The polycythemia vera treatment market in the Europe is set to grow significantly during the estimated period. The increasing enhancement in diagnostic testing in the Europe region is poised to drive the growth of polycythemia vera treatment sector in the region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?